<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RAGWITEK- ambrosia artemisiifolia pollen tablet </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use RAGWITEK safely and effectively. See full prescribing information for RAGWITEK.<br><br>RAGWITEK™ (Short Ragweed Pollen Allergen Extract)<br>Tablet for Sublingual Use<br>Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span><br><span class="Italics">See full prescribing information for complete boxed warning.</span>
</h1>
<ul>
<li><span class="Bold">RAGWITEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer RAGWITEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#S4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span><br><span class="Italics">See full prescribing information for complete boxed warning.</span>
</h1>
<ul>
<li><span class="Bold">RAGWITEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer RAGWITEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#S4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, confirmed by positive skin test or <span class="Italics">in vitro</span> testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For sublingual use only.</span> </p>
<ul>
<li> One tablet daily. (<a href="#S2.1">2.1</a>)</li>
<li> Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. (<a href="#S2.2">2.2</a>)</li>
<li> Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute. (<a href="#S2.2">2.2</a>)</li>
<li> Administer the first dose of RAGWITEK under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#S2.2">2.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablet, 12 Amb a 1-Unit (Amb a 1-U) (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#S4">4</a>)</li>
<li>History of any severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> or any severe local reaction to sublingual allergen immunotherapy. (<a href="#S4">4</a>)</li>
<li>A history of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the inactive ingredients contained in this product. (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Inform patients of the signs and symptoms of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and instruct them to seek immediate medical care and discontinue therapy should any of these occur. (<a href="#S5.1">5.1</a>)</li>
<li> In case of oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, stop treatment with RAGWITEK to allow complete healing of the oral cavity. (<a href="#S5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>Adverse reactions reported in ≥5% of patients were: <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. (<a href="#S6">6</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2     Epinephrine</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Upper Airway Compromise</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Concomitant Allergen Immunotherapy</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></span></h1>
<ul>
<li><span class="Bold">RAGWITEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer RAGWITEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#S4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">RAGWITEK™ is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, confirmed by positive skin test or <span class="Italics">in vitro </span>testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age.</p>
<p>RAGWITEK is not indicated for the immediate relief of allergic symptoms.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For sublingual use only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dose</h2>
<p class="First">One RAGWITEK tablet daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Administration</h2>
<p class="First">Administer the first dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. After receiving the first dose of RAGWITEK, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. If the patient tolerates the first dose, the patient may take subsequent doses at home.</p>
<dl>
<dt> </dt>
<dd>Take the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit after carefully removing the foil with dry hands. 										<p class="First">Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.</p>
<p>Wash hands after handling the tablet.</p>
<p>Do not take the tablet with food or beverage. Food or beverage should not be taken for the following 5 minutes after taking the tablet.</p>
</dd>
</dl>
<p>Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. The safety and efficacy of initiating treatment in season have not been established.</p>
<p>Data regarding the safety of restarting treatment after missing a dose of RAGWITEK are limited. In the clinical trials, treatment interruptions for up to seven days were allowed.</p>
<p>Prescribe auto-injectable epinephrine to patients prescribed RAGWITEK and instruct them in the proper use of emergency self-injection of epinephrine <span class="Italics">[see </span><span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">RAGWITEK is available as 12 Amb a 1-Unit (Amb a 1-U) tablets that are white to off-white, circular with a debossed double hexagon on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">RAGWITEK is contraindicated in patients with:</p>
<ul>
<li>Severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>A history of any severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span></li>
<li>A history of any severe local reaction after taking any sublingual allergen immunotherapy</li>
<li>A history of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product <span class="Italics">[see <a href="#S11">Description (11)</a>].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">RAGWITEK can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> which may be life-threatening. In addition, RAGWITEK can cause severe local reactions, including laryngopharyngeal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, which can compromise breathing and be life-threatening. Educate patients to recognize the signs and symptoms of these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and instruct them to seek immediate medical care and discontinue therapy should any of these occur. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may require treatment with epinephrine. <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>.]</span></p>
<p>Administer the initial dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Observe patients in the office for at least 30 minutes following the initial dose of RAGWITEK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     Epinephrine</h2>
<p class="First">Prescribe auto-injectable epinephrine to patients receiving RAGWITEK. Instruct patients to recognize the signs and symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> and in the proper use of emergency auto-injectable epinephrine. Instruct patients to seek immediate medical care upon use of auto-injectable epinephrine and to stop treatment with RAGWITEK. <span class="Italics">[See </span><span class="Italics"><a href="#S17">Patient Counseling Information (17)</a>.]</span></p>
<p>See the epinephrine package insert for complete information.</p>
<p>RAGWITEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</p>
<p>RAGWITEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine. These medications include:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<p class="First"><span class="Underline">Βeta-adrenergic blockers:</span> Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<p class="First"><span class="Underline">Alpha-adrenergic blockers, ergot alkaloids:</span> Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.3"></a><p></p>
<p class="First"><span class="Underline">Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and certain antihistamines:</span> The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.4"></a><p></p>
<p class="First"><span class="Underline">Cardiac glycosides, diuretics:</span> Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Upper Airway Compromise</h2>
<p class="First">RAGWITEK can cause local reactions in the mouth or throat that could compromise the upper airway <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Consider discontinuation of RAGWITEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></h2>
<p class="First">Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> has been reported in association with sublingual tablet immunotherapy <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>. Discontinue RAGWITEK and consider a diagnosis of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> in patients who experience severe or persistent gastro-esophageal symptoms including <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Subjects with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who participated in clinical trials had <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> of a severity that required, at most, a daily low dose of an inhaled corticosteroid. RAGWITEK has not been studied in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Withhold immunotherapy with RAGWITEK if the patient is experiencing an acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbation. Reevaluate patients who have recurrent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbations and consider discontinuation of RAGWITEK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Concomitant Allergen Immunotherapy</h2>
<p class="First">RAGWITEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">Stop treatment with RAGWITEK to allow complete healing of the oral cavity in patients with oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (e.g., oral <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcers</span>, or <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">thrush</span>) or oral <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, such as those following oral surgery or dental extraction.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions reported in ≥5% of patients were: <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice<span class="Italics">.</span></p>
<p>In 4 placebo-controlled clinical trials, 1057 subjects 18 years of age and older with short ragweed pollen-induced <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, received at least one dose of RAGWITEK, of whom 327 (31%) completed at least 12 weeks of therapy. Of the subjects treated with RAGWITEK, 52% were male, 25% had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and 82% were sensitized to other allergens in addition to ragweed pollen. The subject population was 83% White, 12% African American, and 2% Asian. Subject demographics in placebo-treated subjects were similar to the active group. The pooled analysis includes safety data from two 28-day safety studies and safety data from the first 28 days of two 52-week safety and efficacy studies. Adverse reactions reported in ≥1% of subjects in the 28-day pooled analysis treated with RAGWITEK are shown in Table 1.</p>
<p>The most common adverse reactions reported in subjects treated with RAGWITEK were <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span> (16.6% vs 3.3% placebo), oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (10.9% vs 2.0%), ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (10.4% vs 1.1%), and oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span> (10.0% vs 4.0%). The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to RAGWITEK or placebo was 4.4% and 0.8%, respectively. The most common adverse reactions that led to study discontinuation in subjects who were exposed to RAGWITEK were mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span>, and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>.</p>
<p>One subject (1/1057; 0.1%) who received RAGWITEK experienced a treatment-related severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> that led to discontinuation of RAGWITEK. The subject had local reactions starting on Day 1 of treatment with RAGWITEK. On Day 6 symptoms progressed and included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the throat, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>. The subject fully recovered after treatment with epinephrine (self-administered), antihistamines, and oral corticosteroids.</p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1: Adverse Reactions Reported in ≥1% of Subjects Treated with RAGWITEK (28-day pooled analysis)</span></caption>
<col align="left" valign="top" width="57%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="21%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Adverse Reaction</th>
<th class="Rrule" align="center">RAGWITEK<br>(N=1057)</th>
<th class="Rrule" align="center">Placebo<br>(N=757)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Ear and Labyrinth Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">10.4%</td>
<td class="Rrule" align="center">1.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></td>
<td class="Rrule" align="center">16.6%</td>
<td class="Rrule" align="center">3.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">0.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span></td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">10.9%</td>
<td class="Rrule" align="center">2.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">Paraesthesia oral</span></td>
<td class="Rrule" align="center">10.0%</td>
<td class="Rrule" align="center">4.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">6.1%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">5.1%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">Lip swelling</span></td>
<td class="Rrule" align="center">3.0%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen tongue</span></td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lip <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">0.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">Tongue edema</span></td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Palatal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">1.8%</td>
<td class="Rrule" align="center">1.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
<p>The overall safety profile beyond Day 28 in the two 52-week trials was similar to that observed in the pooled 28-day analysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C:</span></p>
<p>Animal reproduction studies have not been performed with RAGWITEK. It is also not known whether RAGWITEK can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RAGWITEK should be used during pregnancy only if clearly needed.</p>
<p>Because systemic and local adverse reactions with immunotherapy may be poorly tolerated during pregnancy, RAGWITEK should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if RAGWITEK is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RAGWITEK is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">RAGWITEK is not approved for use in pediatric patients because safety and efficacy have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">RAGWITEK tablets contain pollen allergen extract from Short Ragweed (<span class="Italics">Ambrosia artemisiifolia</span>). RAGWITEK is a sublingual orally disintegrating tablet that dissolves rapidly.</p>
<p>RAGWITEK is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract.</p>
<p>Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanisms of action of allergen immunotherapy are not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK<span class="Italics">.</span></p>
<p>There were no positive findings in a combined <span class="Italics">in vivo</span> Comet and micronucleus assay in rats using Short Ragweed (<span class="Italics">Ambrosia artemisiifolia</span>) pollen allergen extract.</p>
<p>Fertility studies have not been performed with Short Ragweed pollen allergen extract.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First">The efficacy of RAGWITEK in the treatment of ragweed pollen-induced <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, was investigated in two double-blind, placebo-controlled clinical trials in adults 18 through 50 years of age. Subjects received RAGWITEK or placebo for approximately 12 weeks prior to the start of the ragweed pollen season and throughout the ragweed pollen season.</p>
<p>The subject population was 86% White, 9% African American, and 3% Asian. The subject population was almost equally divided between males and females. Overall, the mean age of subjects was 36 years. Subjects with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who participated in clinical trials had <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Approximately 16% of subjects had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> at baseline.</p>
<p>Efficacy was established by self-reporting of rhinoconjunctivitis daily symptom scores (DSS) and daily medication scores (DMS). Daily rhinoconjunctivitis symptoms included four nasal symptoms (<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose), and two ocular symptoms (gritty/<span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">itchy eyes</span> and watery eyes). The rhinoconjunctivitis symptoms were measured on a scale of 0 (none) to 3 (severe). Subjects in clinical trials were allowed to take symptom-relieving medications (including systemic and topical antihistamines, and topical and oral corticosteroids) as needed. The daily medication score measured the use of standard open-label <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> medications. Predefined values were assigned to each class of medication. Generally, systemic and topical antihistamines were given the lowest score, topical steroids an intermediate score, and oral corticosteroids the highest score.</p>
<p>The sums of the DSS and DMS were combined into the Total Combined Score (TCS) which was averaged over the peak ragweed pollen season. Also, in each study, the average TCS over the entire ragweed season was assessed. Other endpoints in both studies included the average DSS during the peak and entire ragweed season, and the average DMS during the peak ragweed season.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Italics">Trial 1</span></p>
<p>The first study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=187) and placebo (n=188) administered as a sublingual tablet daily. In this trial, approximately 22% of subjects had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 85% were sensitized to other allergens in addition to short ragweed. Subjects with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who participated in this trial had <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial. The subject population was 78% White, 12% African American, and 8% Asian, and almost equally divided between males and females. The mean age of subjects in this study was 35.4 years. The two treatment groups were balanced with regard to baseline characteristics. The results of this study are shown in Table 2.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Italics">Trial 2</span></p>
<p>The second study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=194) and placebo (n=198) administered as a sublingual tablet daily. Approximately 17% of subjects had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 78% were sensitized to other allergens in addition to short ragweed. Subjects with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who participated in this trial had <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial. The subject population was 88% White, 8.9% African American, 2% Asian, and almost equally divided between males and females. The mean age of subjects in this study was 36.4 years. The two treatment groups were balanced with regard to baseline characteristics. The results of this study are shown in Table 3.</p>
<p>A decrease in TCS during the peak ragweed season for subjects treated with RAGWITEK compared to placebo-treated subjects was demonstrated in both trials. Subjects treated with RAGWITEK also showed a decrease in the average TCS from the start of and throughout the entire ragweed pollen season. Similar decreases were observed in subjects treated with RAGWITEK for other endpoints (see <a href="#table2">Tables 2</a> and <a href="#table3">3</a>).</p>
<a name="table2"></a><table width="90%">
<caption><span>Table 2: Trial 1: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS), and Daily Medication Scores (DMS) During the Ragweed Pollen Season</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center" valign="middle">Endpoint<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">RAGWITEK <br>(N)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br> Score<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Placebo <br>(N)<a href="#footnote-2" class="Sup">†</a><br> Score<a href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center" valign="top">Treatment Difference <br>(RAGWITEK – Placebo)</th>
<th class="Rrule" align="center">Difference Relative to Placebo<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a><br>Estimate<br>(95% CI) 															</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Parametric analysis using analysis of variance model for all endpoints.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Number of subjects in analyses.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>The estimated group means are reported and difference relative to placebo is based on estimated group means.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Difference relative to placebo computed as: (RAGWITEK - placebo)/placebo × 100.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Peak ragweed season was defined as maximum 15 days with the highest moving average pollen counts during the ragweed season.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Bold">TCS <br>Peak Season</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">(159) <br> 6.22</td>
<td class="Rrule" align="center">(164) <br> 8.46</td>
<td class="Rrule" align="center" valign="bottom">-2.24</td>
<td class="Rrule" align="center">-26%<br>(-38.7, -14.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">TCS <br>Entire Season</span></td>
<td class="Rrule" align="center">(160)  <br> 5.21</td>
<td class="Rrule" align="center">(166)  <br> 7.01</td>
<td class="Rrule" align="center" valign="bottom">-1.80</td>
<td class="Rrule" align="center">-26%<br>(-37.6, -13.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS <br>Peak Season</span></td>
<td class="Rrule" align="center">(159) <br> 4.65</td>
<td class="Rrule" align="center">(164) <br> 5.59</td>
<td class="Rrule" align="center" valign="bottom">-0.94</td>
<td class="Rrule" align="center">-17%<br>(-28.6, -4.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS <br>Entire Season</span></td>
<td class="Rrule" align="center">(160) <br> 4.05</td>
<td class="Rrule" align="center">(166) <br> 4.87</td>
<td class="Rrule" align="center" valign="bottom">-0.82</td>
<td class="Rrule" align="center">-17%<br>(-28.5, -4.5)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">DMS <br>Peak Season</span></td>
<td class="Rrule" align="center">(159) <br> 1.57</td>
<td class="Rrule" align="center">(164) <br> 2.87</td>
<td class="Rrule" align="center" valign="bottom">-1.30</td>
<td class="Rrule" align="center">-45%<br>(-65.4, -27.0)</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="90%">
<caption><span>Table 3: Trial 2: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS), and Daily Medication Scores (DMS) During the Ragweed Pollen Season</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center" valign="middle">Endpoint<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
<th class="Rrule" align="center">RAGWITEK <br>(N)<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a><br> Score<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Placebo <br>(N)<a href="#footnote-7" class="Sup">†</a><br> Score<a href="#footnote-8" class="Sup">‡</a>
</th>
<th class="Rrule" align="center" valign="top">Treatment Difference <br>(RAGWITEK – Placebo)</th>
<th class="Rrule" align="center">Difference Relative to Placebo<a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a><br>Estimate<br>(95% CI) 															</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Parametric analysis using analysis of variance model for all endpoints.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Number of subjects in analyses.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>The estimated group means are reported and difference relative to placebo is based on estimated group means.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Difference relative to placebo computed as: (RAGWITEK - placebo)/placebo × 100.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>Peak ragweed season was defined as maximum 15 days with the highest moving average pollen counts during the ragweed season.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Bold">TCS <br>Peak Season</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">(152)<br>6.41</td>
<td class="Rrule" align="center">(169)<br>8.46</td>
<td class="Rrule" align="center" valign="bottom">-2.04</td>
<td class="Rrule" align="center">-24%<br>(-36.5, -11.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">TCS <br>Entire Season</span></td>
<td class="Rrule" align="center">(158)<br>5.18</td>
<td class="Rrule" align="center">(174)<br>7.09</td>
<td class="Rrule" align="center" valign="bottom">-1.92</td>
<td class="Rrule" align="center">-27%<br>(-38.8, -14.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS <br>Peak Season</span></td>
<td class="Rrule" align="center">(152) <br>4.43</td>
<td class="Rrule" align="center">(169)<br>5.37</td>
<td class="Rrule" align="center" valign="bottom">-0.94</td>
<td class="Rrule" align="center">-18%<br>(-29.2, -4.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS <br>Entire Season</span></td>
<td class="Rrule" align="center">(158) <br>3.62</td>
<td class="Rrule" align="center">(174)<br>4.58</td>
<td class="Rrule" align="center" valign="bottom">-0.96</td>
<td class="Rrule" align="center">-21%<br>(-31.6, -8.8)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">DMS <br>Peak Season</span></td>
<td class="Rrule" align="center">(152) <br>1.99</td>
<td class="Rrule" align="center">(169)<br>3.09</td>
<td class="Rrule" align="center" valign="bottom">-1.10</td>
<td class="Rrule" align="center">-36%<br>(-55.8, -14.6)</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">RAGWITEK 12 Amb a 1-U tablets are white to off-white, circular sublingual tablets with a debossed double hexagon on one side.</p>
<p>RAGWITEK is supplied as follows:</p>
<p>3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 10 tablets (30 tablets total). NDC 0006-5420-30</p>
<p>9 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 10 tablets (90 tablets total). NDC 0006-5420-54</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at controlled room temperature, 20ºC-25ºC (68ºF-77ºF); excursions permitted between 15ºC-30ºC (59ºF-86ºF). Store in the original package until use to protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients to read the FDA-approved patient labeling (Medication Guide) and to keep RAGWITEK and all medicines out of the reach of children.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Advise patients that RAGWITEK may cause life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Educate patients about the signs and symptoms of these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>  <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. The signs and symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Ensure that patients have auto-injectable epinephrine and instruct patients in its proper use. Instruct patients who experience a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to seek immediate medical care, discontinue RAGWITEK, and resume treatment only when advised by a physician to do so. <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>.]</span></p>
<p>Advise patients to read the patient information for epinephrine.</p>
<p>Inform patients that the first dose of RAGWITEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>Because of the risk of upper airway compromise, instruct patients with persistent and escalating adverse reactions in the mouth or throat to discontinue RAGWITEK and to contact their healthcare professional. <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>.]</span></p>
<p>Because of the risk of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, instruct patients with severe or persistent symptoms of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> to discontinue RAGWITEK and to contact their healthcare professional. <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Instruct patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> that if they have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> or if their <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> becomes difficult to control, they should stop taking RAGWITEK and contact their healthcare professional immediately <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Underline">Administration Instructions</span></p>
<p>Instruct patients to carefully remove the foil from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet. <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by:<br>Catalent Pharma Solutions Limited, Blagrove,<br>Swindon, Wiltshire, SN5 8RU UK</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.<br></span>All rights reserved.</p>
<p>uspi-mk3641-sb-1406r001 </p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-15"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">RAGWITEK™ (RAG-wi-tek)<br>(Short Ragweed Pollen Allergen Extract)</span></p>
<p>Carefully read this Medication Guide before you start taking RAGWITEK™ and each time you get a refill. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or if you want to learn more about RAGWITEK.</p>
<p><span class="Bold">What is the Most Important Information I Should Know about RAGWITEK?</span></p>
<p>RAGWITEK can cause severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be life-threatening. Stop taking RAGWITEK and get medical treatment right away if you have any of the following symptoms after taking RAGWITEK:</p>
<ul>
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li>Trouble swallowing or speaking</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
</ul>
<p>For home administration of RAGWITEK, your doctor will prescribe auto-injectable epinephrine, a medicine you can inject if you have a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> after taking RAGWITEK. Your doctor will train and instruct you on the proper use of auto-injectable epinephrine.</p>
<p>Talk to your doctor or read the epinephrine patient information if you have any questions about the use of auto-injectable epinephrine.</p>
<p><span class="Bold">What is RAGWITEK?</span></p>
<p>RAGWITEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat ragweed pollen allergies that can cause <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, runny or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose, stuffy or congested nose, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> and watery eyes. RAGWITEK may be prescribed for persons 18 through 65 years of age who are allergic to ragweed pollen.</p>
<p>RAGWITEK is taken for about 12 weeks before ragweed pollen season and throughout ragweed pollen season.</p>
<p>RAGWITEK is NOT a medication that gives immediate relief for symptoms of ragweed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
<p><span class="Bold">Who Should Not Take RAGWITEK?</span></p>
<p>You should not take RAGWITEK if:</p>
<ul>
<li>You have severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>You had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> in the past that included any of these symptoms: 						<ul>
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
</ul>
</li>
<li>You have ever had difficulty with breathing due to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the throat or upper airway after using any sublingual immunotherapy before.</li>
<li>You have ever been diagnosed with eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</li>
<li>You are allergic to any of the inactive ingredients contained in RAGWITEK. The inactive ingredients contained in RAGWITEK are: gelatin, mannitol, and sodium hydroxide.</li>
</ul>
<p><span class="Bold">What Should I Tell My Doctor Before Taking RAGWITEK?</span></p>
<p>Your doctor may decide that RAGWITEK is not the best treatment if:</p>
<ul>
<li>You have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, depending on how severe it is.</li>
<li>You suffer from <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>)</li>
<li>You suffer from heart disease such as <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, an irregular heart rhythm, or you have <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that is not well controlled.</li>
<li>You are pregnant, plan to become pregnant during the time you will be taking RAGWITEK, or are breast-feeding.</li>
<li>You are unable or unwilling to administer auto-injectable epinephrine to treat a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to RAGWITEK.</li>
<li>You are taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction. These medicines include: 						<ul>
<li>beta blockers and alpha-blockers (prescribed for high blood pressure)</li>
<li>cardiac glycosides (prescribed for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or problems with heart rhythm)</li>
<li>diuretics (prescribed for heart conditions and high blood pressure)</li>
<li>ergot alkaloids (prescribed for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>)</li>
<li>monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>)</li>
<li>thyroid hormone (prescribed for low thyroid activity).</li>
</ul>
</li>
<li>You are receiving <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> shots or other immunotherapy under the tongue. Use of more than one of these types of medicines together may increase the likelihood of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</li>
</ul>
<p>You should tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal supplements. Keep a list of them and show it to your doctor and pharmacist each time you get a new supply of RAGWITEK. Ask your doctor or pharmacist for advice before taking RAGWITEK.</p>
<p>RAGWITEK is not indicated for use in children under 18 years of age.</p>
<p><span class="Bold">Are there any Reasons to Stop Taking RAGWITEK?</span></p>
<p>Stop RAGWITEK and contact your doctor if you have any of the following after taking RAGWITEK:</p>
<ul>
<li>Any type of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span></li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> that worsens or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat that causes trouble speaking, breathing, or swallowing</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> or any other breathing condition that gets worse</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>, difficulty swallowing, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with swallowing, or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away or worsens</li>
</ul>
<p>Also, stop taking RAGWITEK following: mouth surgery procedures (such as tooth removal), or if you develop any mouth <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> or cuts in the mouth or throat.</p>
<p><span class="Bold">How Should I Take RAGWITEK?</span></p>
<p>Take RAGWITEK exactly as your doctor tells you.</p>
<p>RAGWITEK is a prescription medicine that is placed under the tongue.</p>
<ul>
<li>Take the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package after carefully removing the foil with dry hands.</li>
<li>Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.</li>
<li>Do not take RAGWITEK with food or beverage. Food and beverage should not be taken for the following 5 minutes.</li>
<li>Wash hands after taking the tablet.</li>
</ul>
<p>Take the first tablet of RAGWITEK in your doctor's office. After taking the first tablet, you will be watched for at least 30 minutes for symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>If you tolerate the first dose of RAGWITEK, you will continue RAGWITEK therapy at home by taking one tablet every day.</p>
<p>Take RAGWITEK as prescribed by your doctor until the end of the treatment course. If you forget to take RAGWITEK, do not take a double dose. Take the next dose at your normal scheduled time the next day. If you miss more than one dose of RAGWITEK, contact your healthcare provider before restarting.</p>
<p><span class="Bold">What are the Possible Side Effects of RAGWITEK?</span></p>
<p>The most commonly reported side effects were <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the mouth, lips, or tongue, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> under the tongue, or <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>. These side effects, by themselves, were not dangerous or life-threatening.</p>
<p>RAGWITEK can cause severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be life-threatening. Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to RAGWITEK include:</p>
<ul>
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li>Trouble swallowing or speaking</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
</ul>
<p>For additional information on the possible side effects of RAGWITEK talk with your doctor or pharmacist. You may report side effects to the U.S. Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<p><span class="Bold">How Should I Store RAGWITEK?</span></p>
<p>Keep RAGWITEK out of the reach of children.</p>
<p>Throw away any unused RAGWITEK after the expiration date which is stated on the carton and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack after "EXP."</p>
<p>Store RAGWITEK in a dry place at room temperature, 15ºC to 30ºC (59ºF to 86ºF), in the original package.</p>
<p><span class="Bold">General Information about RAGWITEK</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use RAGWITEK for a condition for which it was not prescribed. Do not give RAGWITEK to other people, even if they have the same symptoms. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about RAGWITEK. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about RAGWITEK that was written for healthcare professionals. For more information, go to: www.ragwitek.com or call 1-800-622-4477 (toll-free).</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by:<br>Catalent Pharma Solutions Limited, Blagrove,<br>Swindon, Wiltshire, SN5 8RU UK</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.<br></span>All rights reserved.</p>
<p>Revised: 02/2015</p>
<p>usmg-mk3641-sb-1502r001</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton</h1>
<p class="First">NDC 0006-5420-30<br>This carton contains 30 sublingual tablets in three 10-Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards</p>
<p><span class="Bold">Short Ragweed Pollen Allergen Extract,<br>Ragwitek™ Tablet for sublingual use</span></p>
<p><span class="Bold">12 Amb a 1-U</span></p>
<p>For Adults 18 to 65 Years of Age</p>
<p>Each Ragwitek tablet contains 12 Amb a 1-U of short ragweed pollen allergen extract.</p>
<p>Dispense the enclosed Medication Guide to the patient.</p>
<p><span class="Bold">Keep this and all drugs out of the reach of children.</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=986abfaf-67fc-47fb-8c86-d9f9cce6fa8b&amp;name=ragwitek-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RAGWITEK 		
					</strong><br><span class="contentTableReg">short ragweed pollen allergen extract tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">STANDARDIZED ALLERGENIC</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-5420</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMBROSIA ARTEMISIIFOLIA POLLEN</strong> (AMBROSIA ARTEMISIIFOLIA POLLEN) </td>
<td class="formItem">AMBROSIA ARTEMISIIFOLIA POLLEN</td>
<td class="formItem">12 [Amb'a'1'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MARINE COLLAGEN, SOLUBLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-5420-30</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-5420-01</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0006-5420-54</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0006-5420-01</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0006-5420-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125478</td>
<td class="formItem">04/17/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ALK-Abello A S</td>
<td class="formItem"></td>
<td class="formItem">306020926</td>
<td class="formItem">API MANUFACTURE(0006-5420)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions Limited</td>
<td class="formItem"></td>
<td class="formItem">237676320</td>
<td class="formItem">MANUFACTURE(0006-5420)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">101740835</td>
<td class="formItem">PACK(0006-5420)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7a20e56c-dfef-4667-91a6-f808c3445800</div>
<div>Set id: 986abfaf-67fc-47fb-8c86-d9f9cce6fa8b</div>
<div>Version: 5</div>
<div>Effective Time: 20150210</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
